Webinar Clinical Innovation: Making Patient Centricity a Reality



15:30 - 17:00

When “stay at home” became the norm, clinical trials had to follow suit and evolve at lightning speed. Remote monitoring, at-home delivery of drugs, new methods of self-reporting… a lot of innovations in clinical research accelerated. As a “side-effect” it became clear that many study participants actually considered some of these changes as favorable. While clinical study designs had already been moving towards a more patient-centric approach, the pandemic is likely accelerating their development and opening new doors.*

So where do we stand on making clinical development more patient-centric? Are the emergence of platform trials, the use of real-world data, involving patient insights in clinical trial design, and decentralised care having an impact on how new potential healthcare solutions are being developed?

During this session we will explore novel approaches to clinical study designs and methods looking at the future of clinical development from the perspectives of academia, biotech and pharma. We will discuss the evolution and potential impact of key innovations in clinical research and clinical care, and how they aim to contribute to accelerate drug development.

*Source: https://www.appliedclinicaltrialsonline.com/view/sharpening-the-focus-on-patient-centricity-as-pandemic-continues 


15:30 - Welcome & Introduction

15:35 - New approaches for clinical development
Cécile Spiertz | Janssen Pharmaceutical Companies of Johnson & Johnson
Jessica Holthuizen | Johnson & Johnson Clinical Operations

16:05 - Trials @ Home
Rick Grobbee | UMC Utrecht

16:25 - A biotech start-up perspective
Diderik Boot | Prilenia

16:45 - Panel Q&A

17:00 - Close

Cookie consent

This website uses cookies. Cookies are textfiles that are stored on the users harddrive when they visit a website, they are used to make websites function efficiently and serve information to the the owner of the website. Please accept the cookies to use the website properly.